Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's average EBITDA Per Share Growth Rate was 21.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 49.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 54.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gen Ilac Veglik Urunlerinayi ve Ticaret AS was 66.40% per year. The lowest was 49.50% per year. And the median was 58.50% per year.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS 3-Year EBITDA Growth Rate Related Terms
IST:GENIL vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gen Ilac Veglik Urunlerinayi ve Ticaret AS's 3-Year EBITDA Growth Rate falls into.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 49.50% mean?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a 3-Year EBITDA Growth Rate of 49.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is 15% below median its historical median of 58.50. Over the past decade, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's 3-Year EBITDA Growth Rate has ranged from 49.50 to 66.40. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #89 out of 809 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's 3-Year EBITDA Growth Rate too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current 3-Year EBITDA Growth Rate of 49.50% is 15% below median its 10-year median of 58.50. Over the past 10 years, this metric has ranged from a low of 49.50 to a high of 66.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 49.50% is 462.5% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #89 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #89 out of 809 companies for 3-Year EBITDA Growth Rate. This places Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 49.50% is 462.5% above this benchmark. Historically, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's own 3-Year EBITDA Growth Rate has ranged from 49.50 to 66.40 over the past decade. While the company's 10-year median is 58.50 vs. the industry median of 8.80, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current 3-Year EBITDA Growth Rate of 49.50% is 462.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current 3-Year EBITDA Growth Rate is 49.50%, which is 15% below median its own 10-year median of 58.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺8.27, compared to a current price of ₺11.39 — trading 37.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 49.50%, which is 15% below median its 10-year median of 58.50 and 462.5% above the Drug Manufacturers industry median of 8.80. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current 3-Year EBITDA Growth Rate is 49.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺11.39 is trading 37.7% above its estimated GF Value™ of ₺8.27.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Significantly Overvalued.
Key valuation signals for IST:GENIL:
3-Year EBITDA Growth Rate: 49.50% (15% below median its 10-year median of 58.50)
GF Value™: ₺8.27 vs. price of ₺11.39 (37.7% above fair value)
Industry Position: 462.5% above the Drug Manufacturers median (#89 of 809)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
85GF Score
Get the complete analysis for IST:GENIL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
